Fund shareholders of Edgewise Therapeutics Inc
ISIN US28036F1057 · United States
- Fund shareholders
- 215
- Of which ETFs
- 44 171 other funds
- Value held
- 659.2M $ 1.7M € · 71.3M SEK
- Share of capital
- 19.7 % of 108.6M shares on Jul 31, 2026
| Fund | Shares | Value | Weight in fund | Share of capital | |
|---|---|---|---|---|---|
| Wilshire 5000 Index Fund Wilshire Mutual Funds Inc | 230 | 7.2K $ | 0.00 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP ULTRA SMALL CAP ProFunds | 226 | 7.1K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| PROFUND VP SMALL CAP ProFunds | 171 | 5.4K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 Fund Rydex Series Funds | 152 | 4.8K $ | 0.04 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Kennedy Capital Small Cap Growth Fund INVESTMENT MANAGERS SERIES TRUST II | 143 | 4.5K $ | 0.91 % | 0.00 % | as of Mar 31, 2026 ↗ |
| SMALL-CAP PROFUND ProFunds | 123 | 3.8K $ | 0.05 % | 0.00 % | as of Apr 30, 2026 ↗ |
| Columbia Research Enhanced Small Cap ETF Columbia ETF Trust I | 116 | 3.7K $ | 0.12 % | 0.00 % | as of Mar 31, 2026 ↗ |
| Russell 2000 1.5x Strategy Fund Rydex Series Funds | 91 | 2.9K $ | 0.05 % | 0.00 % | as of Mar 31, 2026 ↗ |
| ProShares Hedge Replication ETF ProShares Trust | 69 | 2.1K $ | 0.01 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Goldman Sachs MSCI World Private Equity Return Tracker ETF Goldman Sachs ETF Trust | 35 | 1.1K $ | 0.00 % | 0.00 % | as of Feb 28, 2026 ↗ |
| E*TRADE No Fee Total Market Index Fund E Trade Trust | 30 | 928.8 $ | 0.00 % | 0.00 % | as of Apr 30, 2026 ↗ |
| ProShares Russell 2000 Dynamic Buffer ETF ProShares Trust | 22 | 669.7 $ | 0.06 % | 0.00 % | as of Feb 28, 2026 ↗ |
| Russell 2000(R) 1.5x Strategy Fund Rydex Variable Trust | 18 | 567 $ | 0.02 % | 0.00 % | as of Mar 31, 2026 ↗ |
| VIFAG 2002, SICAV S.A. GESALCALA, S.A., S.G.I.I.C. | 1.1M € | 1.28 % | as of Dec 31, 2025 ↗ | ||
| LAGO ERIE, SICAV, S.A. GESALCALA, S.A., S.G.I.I.C. | 634.9K € | 1.70 % | as of Dec 31, 2025 ↗ |
The funds most exposed to it
The weight is the share of a fund's net assets. The holders table ranks funds by number of shares. This one ranks them by the weight of the company in each fund.
| Fund | Weight in fund | |
|---|---|---|
| iShares Neuroscience and Healthcare ETF iShares Trust | 2.53 % | as of Apr 30, 2026 ↗ |
| ALPS Medical Breakthroughs ETF ALPS ETF TRUST | 2.08 % | as of Feb 28, 2026 ↗ |
| State Street(R) SPDR(R) S&P(R) Pharmaceuticals ETF SPDR SERIES TRUST | 1.95 % | as of Mar 31, 2026 ↗ |
| PROFUND VP PHARMACEUTICALS ProFunds | 1.87 % | as of Mar 31, 2026 ↗ |
| LAGO ERIE, SICAV, S.A. GESALCALA, S.A., S.G.I.I.C. | 1.70 % | as of Dec 31, 2025 ↗ |
| Victory Pioneer Select Mid Cap Growth VCT Portfolio Victory Variable Insurance Funds II | 1.45 % | as of Mar 31, 2026 ↗ |
| Direxion Daily Pharmaceutical & Medical Bull 3X Shares Direxion Shares ETF Trust | 1.34 % | as of Apr 30, 2026 ↗ |
| PHARMACEUTICALS ULTRASECTOR PROFUND ProFunds | 1.32 % | as of Apr 30, 2026 ↗ |
| Invesco Dorsey Wright Healthcare Momentum ETF Invesco Exchange-Traded Fund Trust | 1.31 % | as of Apr 30, 2026 ↗ |
| Victory Pioneer Select Mid Cap Growth Fund Victory Portfolios IV | 1.31 % | as of Feb 28, 2026 ↗ |
Quarter after quarter
Each row is one quarter of SEC filings, newest first. The change compares each quarter with the one before.
| Quarter | Shareholders | Change | Shares | Change |
|---|---|---|---|---|
| 2026Q2 | 211 | +16 | 21,165,786 | +11.8 % |
| 2026Q1 | 195 | +18 | 18,929,524 | +12.3 % |
| 2025Q4 | 177 | -2 | 16,851,193 | -9.7 % |
| 2025Q3 | 179 | -13 | 18,652,517 | +10.9 % |
| 2025Q2 | 192 | +2 | 16,821,936 | +5.5 % |
| 2025Q1 | 190 | +14 | 15,938,655 | -3.7 % |
| 2024Q4 | 176 | +10 | 16,548,536 | +0.2 % |
| 2024Q3 | 166 | +9 | 16,508,168 | +1.0 % |
| 2024Q2 | 157 | +18 | 16,339,201 | +20.1 % |
| 2024Q1 | 139 | +5 | 13,600,494 | +9.3 % |
| 2023Q4 | 134 | 12,437,998 |
Institutional managers
207 managers declare this company to the SEC (Form 13F). The table shows the 25 largest.
| Manager | Shares | Value | |
|---|---|---|---|
| ORBIMED ADVISORS LLC | 15,518,492 | 488.8M $ | as of Mar 31, 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 10,428,437 | 328.5M $ | as of Mar 31, 2026 |
| Paradigm Biocapital Advisors LP | 7,365,038 | 232M $ | as of Mar 31, 2026 |
| BAKER BROS. ADVISORS LP | 6,575,940 | 207.1M $ | as of Mar 31, 2026 |
| BlackRock, Inc. | 6,472,991 | 203.9M $ | as of Mar 31, 2026 |
| JANUS HENDERSON GROUP PLC | 5,915,556 | 186.3M $ | as of Mar 31, 2026 |
| NOVO HOLDINGS A/S | 5,350,000 | 168.5M $ | as of Mar 31, 2026 |
| Driehaus Capital Management LLC | 4,477,942 | 141.1M $ | as of Mar 31, 2026 |
| Siren, L.L.C. | 4,430,263 | 139.6M $ | as of Mar 31, 2026 |
| PERCEPTIVE ADVISORS LLC | 4,423,974 | 139.4M $ | as of Mar 31, 2026 |
| Cormorant Asset Management, LP | 3,260,000 | 102.7M $ | as of Mar 31, 2026 |
| BRAIDWELL LP | 2,347,583 | 73.9M $ | as of Mar 31, 2026 |
| MORGAN STANLEY | 2,246,028 | 70.7M $ | as of Mar 31, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | 1,789,819 | 56.4M $ | as of Mar 31, 2026 |
| ALLIANCEBERNSTEIN L.P. | 1,722,169 | 42.7M $ | as of Mar 31, 2026 |
| STATE STREET CORP | 1,716,823 | 54.1M $ | as of Mar 31, 2026 |
| MPM BIOIMPACT LLC | 1,660,696 | 52.3M $ | as of Mar 31, 2026 |
| Integral Health Asset Management, LLC | 1,600,000 | 50.4M $ | as of Mar 31, 2026 |
| Bellevue Group AG | 1,528,518 | 48.1M $ | as of Mar 31, 2026 |
| Soleus Capital Management, L.P. | 1,449,915 | 45.7M $ | as of Mar 31, 2026 |
| BANK OF AMERICA CORP /DE/ | 1,327,360 | 41.8M $ | as of Mar 31, 2026 |
| UBS Group AG | 1,311,125 | 41.3M $ | as of Mar 31, 2026 |
| DIMENSIONAL FUND ADVISORS LP | 1,219,717 | 38.4M $ | as of Mar 31, 2026 |
| AMERICAN CENTURY COMPANIES INC | 1,147,176 | 36.1M $ | as of Mar 31, 2026 |
| FMR LLC | 1,017,052 | 32M $ | as of Mar 31, 2026 |
Declared shareholders of Edgewise Therapeutics Inc
There are 2 beneficial ownership filings. These stakes do not add up. An asset manager that files includes its own funds, which already appear among the funds on this page.
| Shareholder | Declared stake | Shares | |
|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 5.50 % | 5,915,556 | as of Mar 31, 2026 · SCHEDULE 13G |
| Novo Holdings A/S | 4.90 % | 5,350,000 | as of Apr 23, 2026 · SCHEDULE 13D |
Cite this page
Titelia. "Fund shareholders of Edgewise Therapeutics Inc". https://titelia.com/en/stocks/edgewise-therapeutics-inc-US28036F1057